Skip to content

Study · Randomized controlled trial · 2022

6 results

Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck.

Rooney AM, Dempster DW, Nieves JW, Zhou H, Bostrom MPG, Cosman F

Bone28 Jan 2022Cited by 10 (Europe PMC)

PMID35092891 (opens in a new tab)PMCIDPMC8941636 (opens in a new tab)DOI10.1016/j.bone.2022.116342 (opens in a new tab)PepBankPUB-35092891
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In hip-replacement patients, remodeling-based mineralizing surface was higher with teriparatide than placebo in cancellous and endocortical envelopes.

    In plain wordsIn hip-replacement patients, remodeling-based bone formation surface was higher with teriparatide than placebo in cancellous and endocortical regions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseRemodeling-based mineralizing surface
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · Mean 6.1 weeks (range 4.1-11.8 weeks)As given in this study (human).

    Source sentences

    Summary
    In the cancellous and endocortical envelopes, the proportion of mineralizing surface engaged in RBF and oRBF was higher in the TPTD-treated than the PBO-treated subjects.
    2 context sentences
    Summary · context
    We performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.
    Summary · context
    Participants were randomized to receive daily TPTD 20 μg or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior to THR.
  2. 02HumanRandomized controlled trialMechanism

    In hip-replacement patients, overflow remodeling-based mineralizing surface was higher with teriparatide than placebo in cancellous and endocortical envelopes.

    In plain wordsIn hip-replacement patients, overflow remodeling-based formation surface was higher with teriparatide than placebo in cancellous and endocortical regions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseOverflow remodeling-based mineralizing surface
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · Mean 6.1 weeks (range 4.1-11.8 weeks)As given in this study (human).

    Source sentences

    Summary
    In the cancellous and endocortical envelopes, the proportion of mineralizing surface engaged in RBF and oRBF was higher in the TPTD-treated than the PBO-treated subjects.
    2 context sentences
    Summary · context
    We performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.
    Summary · context
    Participants were randomized to receive daily TPTD 20 μg or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior to THR.
  3. 03HumanRandomized controlled trialMechanism

    In hip-replacement patients, modeling-based formation showed a trend toward higher values with teriparatide than placebo in cancellous and endocortical envelopes.

    In plain wordsIn hip-replacement patients, modeling-based formation tended to be higher with teriparatide than placebo in cancellous and endocortical regions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseModeling-based formation
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · Mean 6.1 weeks (range 4.1-11.8 weeks)As given in this study (human).

    Source sentences

    Summary
    There was also a trend toward higher MBF in TPTD vs. PBO in both envelopes.
    2 context sentences
    Summary · context
    We performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.
    Summary · context
    Participants were randomized to receive daily TPTD 20 μg or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior to THR.
  4. 04HumanRandomized controlled trialMechanism

    In hip-replacement patients, eroded surface did not differ between teriparatide and placebo in cancellous or endocortical envelopes.

    In plain wordsIn hip-replacement patients, eroded bone surface did not differ between teriparatide and placebo in cancellous or endocortical regions.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeEroded surface
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · Mean 6.1 weeks (range 4.1-11.8 weeks)As given in this study (human).

    Source sentences

    Summary
    Eroded surface was not different between groups in either envelope and no significant differences were observed in any parameter in the periosteal envelope.
    2 context sentences
    Summary · context
    We performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.
    Summary · context
    Participants were randomized to receive daily TPTD 20 μg or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior to THR.
  5. 05HumanRandomized controlled trialMechanism

    In hip-replacement patients, no periosteal envelope parameter differed significantly between teriparatide and placebo.

    In plain wordsIn hip-replacement patients, no periosteal bone parameter differed significantly between teriparatide and placebo.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changePeriosteal envelope parameters
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · Mean 6.1 weeks (range 4.1-11.8 weeks)As given in this study (human).

    Source sentences

    Summary
    Eroded surface was not different between groups in either envelope and no significant differences were observed in any parameter in the periosteal envelope.
    2 context sentences
    Summary · context
    We performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.
    Summary · context
    Participants were randomized to receive daily TPTD 20 μg or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior to THR.

Studies that did not test the peptide alone1

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

  1. 06HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyMechanism

    In hip-replacement patients, linear mixed-effects models predicted that teriparatide would increase bone formation differently on tensile and compressive surfaces depending on patient anatomy.

    In plain wordsIn hip-replacement patients, statistical models predicted that teriparatide's effect on bone formation varied with patient anatomy and surface loading.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    MixedAnatomy-dependent regional formation response
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    In linear mixed-effects models, TPTD was predicted to increase formation differently on the tensile and compressive surfaces depending on patient-specific anatomy, including body weight, FN angle, offset, and cortical width and porosity.
    2 context sentences
    Summary · context
    We performed a double-blind trial of TPTD vs. placebo (PBO) in patients about to undergo a total hip replacement (THR) for osteoarthritis.
    Summary · context
    Participants were randomized to receive daily TPTD 20 μg or PBO for an average of 6.1 weeks (range 4.1-11.8 weeks) prior to THR.

    In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.